2023
Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysis
2009
Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005)
Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005). Journal Of Surgical Research 2009, 156: 340-351. PMID: 19577759, PMCID: PMC7371344, DOI: 10.1016/j.jss.2009.04.024.Peer-Reviewed Original ResearchConceptsEnd Results (SEER) databaseSurgical resectionCNS ependymomasMedian survivalResults databaseRadiation therapyMultivariate analysisIntracranial tumor locationOverall median survivalRole of surgeryFive-year survivalSignificant survival benefitLonger median survivalGrade III tumorsPrimary tumor siteLack of radiationMedian agePatient ageSurvival benefitImproved survivalIndependent predictorsAnnual incidenceMalignant ependymomaSurgical extirpationPatient survival